Codeine crackdown could cost $1.27 billion over four years… and more

Upscheduling codeine-containing OTCs could cost upwards of $1.27 billion in MBS outlay alone over the next four years, a new report has found. The Pharmacy Guild engaged Cadence Economics to undertake an analysis of the fiscal impacts of upscheduling all medicines containing codeine to prescription only. Currently there are 16.4 million units sold each year

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Momentum building for switch environment, S3 advertising policy: ASMI
Next ASMI celebrates excellence in quality use of medicines